Nicholas Investment Partners LP increased its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 54.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,961 shares of the medical instruments supplier's stock after buying an additional 11,237 shares during the period. Nicholas Investment Partners LP owned 0.06% of Glaukos worth $4,792,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. IFP Advisors Inc purchased a new position in Glaukos in the 4th quarter worth about $43,000. Asset Planning Inc purchased a new stake in shares of Glaukos in the fourth quarter valued at about $90,000. CoreCap Advisors LLC lifted its position in shares of Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after purchasing an additional 200 shares in the last quarter. Picton Mahoney Asset Management purchased a new position in Glaukos in the fourth quarter valued at approximately $125,000. Finally, SBI Securities Co. Ltd. purchased a new position in shares of Glaukos during the fourth quarter worth approximately $153,000. 99.04% of the stock is owned by institutional investors.
Insider Transactions at Glaukos
In related news, CFO Alex R. Thurman sold 1,520 shares of the stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the transaction, the chief financial officer now directly owns 53,431 shares in the company, valued at $5,708,568.04. This trade represents a 2.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.80% of the company's stock.
Glaukos Price Performance
Shares of GKOS traded down $1.50 during midday trading on Monday, hitting $93.97. The company's stock had a trading volume of 268,584 shares, compared to its average volume of 927,202. Glaukos Co. has a one year low of $77.10 and a one year high of $163.71. The company's fifty day simple moving average is $93.91 and its two-hundred day simple moving average is $125.86. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $5.37 billion, a price-to-earnings ratio of -32.73 and a beta of 0.83.
Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.11. The company had revenue of $106.66 million for the quarter, compared to analyst estimates of $102.78 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The company's revenue for the quarter was up 24.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.70) EPS. As a group, equities analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several analysts have commented on the company. Stephens lowered their price target on Glaukos from $140.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Stifel Nicolaus decreased their target price on Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Mizuho decreased their price target on Glaukos from $200.00 to $175.00 and set an "outperform" rating for the company in a research report on Wednesday, April 16th. Needham & Company LLC reduced their price objective on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Finally, Truist Financial restated a "buy" rating and issued a $135.00 target price (down from $140.00) on shares of Glaukos in a report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $134.67.
Check Out Our Latest Research Report on GKOS
Glaukos Company Profile
(
Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Stories
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
